Literature DB >> 2381632

Hypercalcemia in a calcitriol-treated hypoparathyroid woman during lactation.

R H Caplan1, E A Beguin.   

Abstract

We treated a hypoparathyroid woman with calcitriol during pregnancy and did not reduce the dosage after delivery. Despite lactation, the serum calcium level increased to 15.4 mg/dL 11 days postpartum. We treated two other hypoparathyroid women during four pregnancies with either calcitriol or dihydrotachysterol. In all five pregnancies, requirements for the vitamin D preparations increased beginning at the 20-28th week of gestation. Hypercalcemia did not occur in the two women who did not breast-feed and in whom we reduced the dose of calcitriol or dihydrotachysterol after delivery. We conclude the following: 1) Calcitriol is effective for treating hypoparathyroidism during pregnancy; 2) the dose usually needs to be increased during the latter half of gestation; 3) the calcitriol dose should be reduced during lactation; and 4) both mother and infant should be monitored to detect hypercalcemia during breast-feeding. We speculate that low serum estrogen levels associated with breast-feeding promote bone resorption and diminish calcitriol needs in lactating hypoparathyroid women.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381632

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice.

Authors:  E Papini; R Negro; A Pinchera; R Guglielmi; A Baroli; P Beck-Peccoz; P Garofalo; M P Pisoni; M Zini; R Elisei; L Chiovato
Journal:  J Endocrinol Invest       Date:  2010-07-13       Impact factor: 4.256

Review 2.  Presentation and management of osteoporosis presenting in association with pregnancy or lactation.

Authors:  C S Kovacs; S H Ralston
Journal:  Osteoporos Int       Date:  2015-05-05       Impact factor: 4.507

3.  Prolonged spontaneous normocalcaemia in pseudohypoparathyroidism from resorption of soft tissue calcium deposits: a cautionary tale.

Authors:  Erin E Carter; Gregory Kline
Journal:  BMJ Case Rep       Date:  2014-01-30

4.  Evidence for a role of prolactin in calcium homeostasis: regulation of intestinal transient receptor potential vanilloid type 6, intestinal calcium absorption, and the 25-hydroxyvitamin D(3) 1alpha hydroxylase gene by prolactin.

Authors:  Dare V Ajibade; Puneet Dhawan; Adam J Fechner; Mark B Meyer; J Wesley Pike; Sylvia Christakos
Journal:  Endocrinology       Date:  2010-05-12       Impact factor: 4.736

Review 5.  Calcium and bone metabolism during pregnancy and lactation.

Authors:  Christopher S Kovacs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

Review 6.  Vitamin D: metabolism.

Authors:  Sylvia Christakos; Dare V Ajibade; Puneet Dhawan; Adam J Fechner; Leila J Mady
Journal:  Endocrinol Metab Clin North Am       Date:  2010-06       Impact factor: 4.741

Review 7.  Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature.

Authors:  Elena Tsourdi; Athanasios D Anastasilakis
Journal:  Biomedicines       Date:  2021-04-26

8.  Calcium and bone disorders in pregnancy.

Authors:  Shriraam Mahadevan; V Kumaravel; R Bharath
Journal:  Indian J Endocrinol Metab       Date:  2012-05

9.  Management of hypoparathyroidism in pregnancy and lactation - A report of 10 cases.

Authors:  B L Hatswell; C A Allan; J Teng; P Wong; P R Ebeling; E M Wallace; P J Fuller; F Milat
Journal:  Bone Rep       Date:  2015-06-30

Review 10.  Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus.

Authors:  Aliya A Khan; Christian A Koch; Stan Van Uum; Jean Patrice Baillargeon; Jens Bollerslev; Maria Luisa Brandi; Claudio Marcocci; Lars Rejnmark; Rene Rizzoli; M Zakarea Shrayyef; Rajesh Thakker; Bulent O Yildiz; Bart Clarke
Journal:  Eur J Endocrinol       Date:  2019-03       Impact factor: 6.664

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.